The Enterprise together with AVAC, the Bill & Melinda Gates Foundation and the Treatment Action Group (TAG) hosted a consultation in September on strategic directions for therapeutic vaccines research. Join us on Monday, 18 November at 12:00 EST for a webinar to share highlights from the consultation. You can register for the webinar here, https://cc.readytalk.com/cc/s/registrations/new?cid=68wm0ch6bj72.
More than 450 research studies outlining the latest advances and obstacles in the search for an AIDS vaccine will be presented and debated at AIDS Vaccine 2013, the world's only scientific meeting dedicated exclusively to HIV vaccine research.
The NIH is offering R01 grants to help investigate structural and conformational features of HIV glycosylation that may lead to novel HIV vaccine design approaches; and to elucidate the impact of differential glycosylation on the quality of the immune response to HIV. The deadline to apply is 02 December, http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-12-056.html.
In a brief history of the global effort to develop a preventive HIV vaccine (Vaccine 2013, in press), Enterprise champion, Jose Esparza has set down the highs and lows of 30 years of research and development on HIV vaccines that have brought us where we are today. This is an important contribution because many senior HIV vaccine scientists have forgotten what we did and why we did it and, conversely, many younger scientists are not aware of those past efforts.